Cargando…

Why a Complete Response Is the Treatment Aim in Chronic Spontaneous Urticaria

This study investigated the association between urticaria activity and health-related quality of life (HRQoL). Patient evaluations from the ligelizumab Phase 2b clinical trial (N = 382) were pooled (NCT02477332). Daily patient diaries assessed urticaria activity, sleep and activity interference, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Bernstein, Jonathan A., Giménez-Arnau, Ana, Maurer, Marcus, Staubach, Petra, Barbier, Nathalie, Hua, Eva, Severin, Thomas, Laires, Pedro A., Balp, Maria-Magdalena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219198/
https://www.ncbi.nlm.nih.gov/pubmed/37240667
http://dx.doi.org/10.3390/jcm12103561
_version_ 1785048952217796608
author Bernstein, Jonathan A.
Giménez-Arnau, Ana
Maurer, Marcus
Staubach, Petra
Barbier, Nathalie
Hua, Eva
Severin, Thomas
Laires, Pedro A.
Balp, Maria-Magdalena
author_facet Bernstein, Jonathan A.
Giménez-Arnau, Ana
Maurer, Marcus
Staubach, Petra
Barbier, Nathalie
Hua, Eva
Severin, Thomas
Laires, Pedro A.
Balp, Maria-Magdalena
author_sort Bernstein, Jonathan A.
collection PubMed
description This study investigated the association between urticaria activity and health-related quality of life (HRQoL). Patient evaluations from the ligelizumab Phase 2b clinical trial (N = 382) were pooled (NCT02477332). Daily patient diaries assessed urticaria activity, sleep and activity interference, the dermatology life quality index (DLQI), and work productivity and activity impairment-chronic urticaria (WPAI-CU). The number of DLQI scores, weekly sleep interference scores (SIS7), weekly activity interference scores (AIS7), and overall work impairment (OWI) evaluations with a complete response per weekly urticaria activity score (UAS7) using bands (0, 1–6, 7–15, 16–27, and 28–42) were reported. Over 50% of the patients had a mean DLQI of > 10 at baseline, indicating a significant effect of chronic spontaneous urticaria (CSU) on their HRQoL. Complete response (UAS7 = 0) evaluations corresponded with no impacts on other patient-reported outcomes. In total, 91.1% of UAS7 = 0 evaluations corresponded to DLQI scores of 0–1, 99.7% to SIS7 scores of 0, 99.7% to AIS7 scores of 0, and 85.3% to OWI scores of 0. This was significantly different compared with the UAS7 = 1–6 evaluations (61.9%, 68.5%, 67.7%, and 65.4%, respectively; p < 0.0001). Complete responses to treatment were associated with no impairments on the dermatology-QoL, no interferences with sleep and activity, and significantly improved capacities to work compared to patients who continued to have signs and symptoms, even for those with minimal disease activity.
format Online
Article
Text
id pubmed-10219198
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102191982023-05-27 Why a Complete Response Is the Treatment Aim in Chronic Spontaneous Urticaria Bernstein, Jonathan A. Giménez-Arnau, Ana Maurer, Marcus Staubach, Petra Barbier, Nathalie Hua, Eva Severin, Thomas Laires, Pedro A. Balp, Maria-Magdalena J Clin Med Article This study investigated the association between urticaria activity and health-related quality of life (HRQoL). Patient evaluations from the ligelizumab Phase 2b clinical trial (N = 382) were pooled (NCT02477332). Daily patient diaries assessed urticaria activity, sleep and activity interference, the dermatology life quality index (DLQI), and work productivity and activity impairment-chronic urticaria (WPAI-CU). The number of DLQI scores, weekly sleep interference scores (SIS7), weekly activity interference scores (AIS7), and overall work impairment (OWI) evaluations with a complete response per weekly urticaria activity score (UAS7) using bands (0, 1–6, 7–15, 16–27, and 28–42) were reported. Over 50% of the patients had a mean DLQI of > 10 at baseline, indicating a significant effect of chronic spontaneous urticaria (CSU) on their HRQoL. Complete response (UAS7 = 0) evaluations corresponded with no impacts on other patient-reported outcomes. In total, 91.1% of UAS7 = 0 evaluations corresponded to DLQI scores of 0–1, 99.7% to SIS7 scores of 0, 99.7% to AIS7 scores of 0, and 85.3% to OWI scores of 0. This was significantly different compared with the UAS7 = 1–6 evaluations (61.9%, 68.5%, 67.7%, and 65.4%, respectively; p < 0.0001). Complete responses to treatment were associated with no impairments on the dermatology-QoL, no interferences with sleep and activity, and significantly improved capacities to work compared to patients who continued to have signs and symptoms, even for those with minimal disease activity. MDPI 2023-05-19 /pmc/articles/PMC10219198/ /pubmed/37240667 http://dx.doi.org/10.3390/jcm12103561 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bernstein, Jonathan A.
Giménez-Arnau, Ana
Maurer, Marcus
Staubach, Petra
Barbier, Nathalie
Hua, Eva
Severin, Thomas
Laires, Pedro A.
Balp, Maria-Magdalena
Why a Complete Response Is the Treatment Aim in Chronic Spontaneous Urticaria
title Why a Complete Response Is the Treatment Aim in Chronic Spontaneous Urticaria
title_full Why a Complete Response Is the Treatment Aim in Chronic Spontaneous Urticaria
title_fullStr Why a Complete Response Is the Treatment Aim in Chronic Spontaneous Urticaria
title_full_unstemmed Why a Complete Response Is the Treatment Aim in Chronic Spontaneous Urticaria
title_short Why a Complete Response Is the Treatment Aim in Chronic Spontaneous Urticaria
title_sort why a complete response is the treatment aim in chronic spontaneous urticaria
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219198/
https://www.ncbi.nlm.nih.gov/pubmed/37240667
http://dx.doi.org/10.3390/jcm12103561
work_keys_str_mv AT bernsteinjonathana whyacompleteresponseisthetreatmentaiminchronicspontaneousurticaria
AT gimenezarnauana whyacompleteresponseisthetreatmentaiminchronicspontaneousurticaria
AT maurermarcus whyacompleteresponseisthetreatmentaiminchronicspontaneousurticaria
AT staubachpetra whyacompleteresponseisthetreatmentaiminchronicspontaneousurticaria
AT barbiernathalie whyacompleteresponseisthetreatmentaiminchronicspontaneousurticaria
AT huaeva whyacompleteresponseisthetreatmentaiminchronicspontaneousurticaria
AT severinthomas whyacompleteresponseisthetreatmentaiminchronicspontaneousurticaria
AT lairespedroa whyacompleteresponseisthetreatmentaiminchronicspontaneousurticaria
AT balpmariamagdalena whyacompleteresponseisthetreatmentaiminchronicspontaneousurticaria